For young, healthy people who may be wondering, “do I need a COVID booster at all?”, having one annually is sensible.

Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

Australia is set to get a new COVID vaccine in the next two weeks, but what variant is it targeting? And should we all still ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

It is the first quarter that includes sales of Moderna's vaccine against respiratory syncytial virus, its second-ever commercially available product. Moderna on Thursday posted a surprise profit ...

By Patrick Wingrove (Reuters) -Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue ...

Heading into Moderna’s (Nasdaq: MRNA) third-quarter earnings on Thursday, investors and analysts will be watching to see how the Cambridge drugmaker plans to hit its new financial goals and what ...

Moderna has received Health Canada's approval ... mRESVIA is reportedly currently the only vaccine available in a distinct single-dose prefilled syringe format. This is intended to streamline ...

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and ...

mRESVIA is Moderna's second approved product in Canada ... mRESVIA is the only RSV vaccine available in a pre-filled syringe. This format offers a convenient, ready-to-use formulation that ...